BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20959519)

  • 21. Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus.
    Raja S; Finkelstein SD; Baksh FK; Gooding WE; Swalsky PA; Godfrey TE; Buenaventura PO; Luketich JD
    Ann Thorac Surg; 2001 Oct; 72(4):1130-5. PubMed ID: 11603424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Frequency and significance of APC gene mutations in malignant degeneration of Barrett esophagus].
    Stöltzing O; Schneider PM; Becker K; Wegerer S; Siewert JR; Hölscher AH
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):485-9. PubMed ID: 14518303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations in Barrett's esophagus and esophageal adenocarcinoma.
    Dinjens WN
    Minerva Chir; 2002 Dec; 57(6):733-52. PubMed ID: 12592217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
    Wilson KT
    Dis Esophagus; 2002; 15(1):16-21. PubMed ID: 12060038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p27 and Barrett's esophagus: a review*.
    Ellis FH; Loda M
    Dis Esophagus; 2004; 17(2):113-7. PubMed ID: 15230722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
    Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
    Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
    Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
    Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).
    Cronin J; McAdam E; Danikas A; Tselepis C; Griffiths P; Baxter J; Thomas L; Manson J; Jenkins G
    Am J Gastroenterol; 2011 Jan; 106(1):46-56. PubMed ID: 21157443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis.
    Wang S; Zhan M; Yin J; Abraham JM; Mori Y; Sato F; Xu Y; Olaru A; Berki AT; Li H; Schulmann K; Kan T; Hamilton JP; Paun B; Yu MM; Jin Z; Cheng Y; Ito T; Mantzur C; Greenwald BD; Meltzer SJ
    Oncogene; 2006 Jun; 25(23):3346-56. PubMed ID: 16449976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Kaz AM; Grady WM; Stachler MD; Bass AJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural selection in neoplastic progression of Barrett's esophagus.
    Maley CC; Reid BJ
    Semin Cancer Biol; 2005 Dec; 15(6):474-83. PubMed ID: 16043360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
    J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Walch A; Mueller J; Höfler H; Werner M
    J Natl Cancer Inst; 2000 Jul; 92(14):1182-3. PubMed ID: 10904093
    [No Abstract]   [Full Text] [Related]  

  • 38. Microsatellite analysis provides evidence of neoplastic transformation in long-segment, but not in short-segment, Barrett's oesophagus.
    Gleeson CM; McDougall NI; Russell SE; McGuigan JA; Collins JS; Sloan JM
    Int J Cancer; 2000 Feb; 85(4):482-5. PubMed ID: 10699918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biology of Barrett's esophagus and esophageal adenocarcinoma.
    Wang DH; Souza RF
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):25-38. PubMed ID: 21112495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.